Nykode Therapeutics AS (OSL:NYKD)

Nykode Therapeutics AS Ratios and Metrics

Market cap in millions NOK. Fiscal year is January - December.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Feb 3, 2026	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Market Capitalization	1,019	995	6,988	8,287	23,372	21,356
Market Cap Growth	17.29%	-85.77%	-15.67%	-64.54%	9.44%	-
Enterprise Value	409	-270	5,353	6,040	21,724	21,194
Last Close Price	3.12	1.99	13.98	18.37	52.72	48.99
PE Ratio	-	-	-	-	-	16.64
Forward PE	-	-	-	4.32	4.32	4.32
PS Ratio	13.89	9.56	51.73	93.16	74.18	11.55
PB Ratio	1.03	0.64	4.02	5.36	13.67	13.93
P/TBV Ratio	1.03	0.64	4.03	5.36	13.67	13.93
P/FCF Ratio	-	-	-	-	9341.31	13.83
P/OCF Ratio	-	-	-	-	2296.91	13.82
EV/Sales Ratio	5.58	-	39.62	67.90	68.94	11.46
EV/EBITDA Ratio	-	-	-	-	-	13.87
EV/EBIT Ratio	-	-	-	-	-	13.87
EV/FCF Ratio	-1.15	-	-	-	8682.61	13.73
Debt / Equity Ratio	0.03	0.03	0.03	0.04	0.04	0.00
Debt / EBITDA Ratio	-	-	-	-	-	0.00
Debt / FCF Ratio	-	-	-	-	25.25	0.00
Asset Turnover	0.05	0.05	0.06	0.04	0.14	1.64
Quick Ratio	17.14	12.78	7.94	5.41	8.12	17.36
Current Ratio	17.14	12.87	8.04	5.44	8.16	17.38
Return on Equity (ROE)	-9.10%	-25.25%	-21.42%	-24.35%	-5.05%	145.07%
Return on Assets (ROA)	-12.08%	-16.70%	-16.90%	-13.64%	-2.72%	84.59%
Return on Invested Capital (ROIC)	-71.49%	-250.18%	-	-	-	-
Return on Capital Employed (ROCE)	-26.00%	-33.50%	-31.00%	-29.10%	-4.60%	82.20%
Earnings Yield	-10.79%	-44.34%	-5.10%	-5.08%	-0.36%	6.01%
FCF Yield	-35.07%	-58.58%	-14.30%	-2.78%	0.01%	7.23%
Dividend Yield	31.51%	50.26%	-	-	-	-
Buyback Yield / Dilution	22.32%	-8.66%	-3.58%	-1.32%	3.31%	-1.14%
Total Shareholder Return	53.82%	41.60%	-3.58%	-1.32%	3.31%	-1.14%

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.